戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ould also be effectively delivered orally or intrarectally.
2 d the other half were exposed to SIV(mac251) intrarectally.
3 s SIVmac239, prevents infection by SIVsmE660 intrarectally.
4 mAbs) to rhesus macaques and challenged them intrarectally 24 h later with either of two different R5
5 gnificantly earlier than macaques challenged intrarectally and well past the initial resolution of vi
6 ast vaccination, the animals were challenged intrarectally at weekly intervals with a titrated dose o
7                             The animals were intrarectally challenged 5 days later with SHIV(BG505).
8       During the first month post-challenge, intrarectally challenged monkeys were up to 1 week delay
9 uding cellular targets, rhesus macaques were intrarectally challenged with a single-round simian immu
10 ed rhesus macaques were either uninfected or intrarectally challenged with SIV, with a subset receivi
11 in significant proportions, animals infected intrarectally had predominantly E11S-type sequences.
12                      Animals were inoculated intrarectally (i.r.) or intravenously (i.v.) with stocks
13  with SIVmac239Delta nef and challenged them intrarectally (i.r.) with repeated low doses of the path
14  a major reservoir for virus replication, in intrarectally immunized animals than in subcutaneously i
15 ements, and patterns of coreceptor switch in intrarectally infected animals were thus remarkably cons
16 rliest published example of CD8-TL escape in intrarectally infected macaques.
17 l lines and human cancer cells were injected intrarectally into nonobese diabetic/SCID mice.
18 and four adult AGMs as well as two PTMs were intrarectally (IR) exposed, while two additional adult f
19                       The NPs were instilled intrarectally, limiting delivery to the distal colon.
20  Twenty-nine rhesus macaques were challenged intrarectally or intravenously with either a single dose
21  Fiebig-equivalent stages in NHPs challenged intrarectally or intravenously with SHIVAD8-EO.
22 pe and SIV(SM) Pbj deltaVpx intravenously or intrarectally, the deltaVpx mutant was at a strong compe
23 ed to mimic the RV144 trial and exposed them intrarectally to a dose of the simian immunodeficiency v
24 /gp120, or gp120 alone, and all were exposed intrarectally to SIV(mac251) at one of three doses.
25          Vaccinated macaques were challenged intrarectally with 50 50% animal infectious doses of SHI
26 e infected, 12 male macaques were inoculated intrarectally with amounts of SHIV(SF162P3) (10 median t
27 es were infused with PGDM1400 and challenged intrarectally with either 500 monkey infectious dose 50
28                These animals were challenged intrarectally with pathogenic molecularly cloned SIVmac2
29 he CTL specificity, we immunized BALB/c mice intrarectally with recombinant MVA 89.6.
30 n coreceptor preference in macaques infected intrarectally with SHIV(SF162P3N).
31 dian and Chinese origin were next inoculated intrarectally with SHIV-1157ipd3N4; this virus replicate
32 re prophylaxis in rhesus macaques challenged intrarectally with simian-human immunodeficiency virus (
33 ed and naive control monkeys were challenged intrarectally with SIV strain DeltaB670 (SIV/DeltaB670),
34 ) and Mamu-A*01(-) macaques, were challenged intrarectally with SIVmac239.
35 naive, Mamu-A*01(+) controls were challenged intrarectally with SIVmac239.
36 oculated pigtailed macaques intravenously or intrarectally with the molecularly cloned, macrophage tr